Quick Answer
NEKTAR THERAPEUTICS reported Stockholders Equity of $89.83 million for fiscal year 2025.
NEKTAR THERAPEUTICS Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $89.83M | +47.9% |
| 2024 | $60.74M | -53.6% |
| 2023 | $130.99M | -64.3% |
| 2022 | $366.64M | -46.0% |
| 2021 | $679.51M | -36.9% |
| 2020 | $1.08B | -23.3% |
| 2019 | $1.41B | -18.2% |
| 2018 | $1.72B | +1855.6% |
| 2017 | $87.83M | -0.3% |
| 2016 | $88.12M | +1270.7% |
| 2015 | $6.43M | -82.3% |
| 2014 | $36.33M | +140.4% |
| 2013 | -$89.90M | -291.2% |
| 2012 | $47.02M | -76.2% |
| 2011 | $197.81M | +118.2% |
| 2010 | $90.66M | -11.4% |
| 2009 | $102.37M | -46.2% |
| 2008 | $190.15M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $85.09M | +74.1% | +451.4% |
| June 30, 2025 | -$24.21M | -130.4% | -276.2% |
| March 31, 2025 | $13.74M | -89.2% | -77.4% |
| December 31, 2024 | $60.74M | -53.6% | +24.2% |
| September 30, 2024 | $48.88M | -69.3% | -38.7% |
| June 30, 2024 | $79.69M | -59.5% | -37.1% |
| March 31, 2024 | $126.70M | -47.4% | -3.3% |
| December 31, 2023 | $130.99M | -64.3% | -17.8% |
- NEKTAR THERAPEUTICS showed an increase of +47.9% in Stockholders Equity compared to the prior fiscal year.
- Over the 2008–2025 period, NEKTAR THERAPEUTICS’s stockholders equity has declined by 52.8% (from $190.15 million to $89.83 million).
- The most recent figure is from NEKTAR THERAPEUTICS’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 13, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: